Eesti - eesti - Ravimiamet

panpharma laboratories - ketamiin - süstelahus - 50mg 1ml 10ml 25tk

Eesti - eesti - Ravimiamet

laboratoire chauvin s.a. - oksübuprokaiin - silmatilgad, lahus - 4mg 1ml 0.5ml 20tk

Eesti - eesti - Ravimiamet

ao biopharm - püridoksiin - süstelahus - 50mg 1ml 1ml 10tk

Eesti - eesti - Ravimiamet

pat lubnyfarm - püridoksiin - süstelahus - 50mg 1ml 1ml 10tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

yes pharmaceutical development services gmbh - doksorubitsiini vesinikkloriid - breast neoplasms; ovarian neoplasms; multiple myeloma; sarcoma, kaposi - antineoplastilised ained - celdoxome pegylated liposomal is indicated in adults:as monotherapy for patients with metastatic breast cancer, where there is an increased cardiac risk. or treatment of advanced ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen. in combination with bortezomib for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant. for treatment of aids-related kaposi’s sarcoma (ks) in patients with low cd4 counts (< 200 cd4 lymphocytes/mm3) and extensive mucocutaneous or visceral disease. celdoxome pegylated liposomal may be used as first-line systemic chemotherapy, or as second line chemotherapy in aids-ks patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and standard doxorubicin (or other anthracycline).

Eesti - eesti - Ravimiamet

brooks laboratories limited - püridoksiin - süstelahus - 50mg 1ml 2ml 5tk

Eesti - eesti - Ravimiamet

kimball electronics, inc. - naloksoon - süstelahus eeltäidetud süstevahendis - 10mg 0.4ml 0.4ml 10tk

Eesti - eesti - Ecolab

ecolab deutschland gmbh -

Euroopa Liit - eesti - EMA (European Medicines Agency)

laboratoires delbert - histamiini dihüdrokloriid - leukeemia, müeloidne, äge - immunostimulants, - ceplene maintenance therapy is indicated for adult patients with acute myeloid leukaemia in first remission concomitantly treated with interleukin-2 (il-2). ceplene efektiivsus ei ole täielikult tõestatud üle 60-aastastel patsientidel.

Euroopa Liit - eesti - EMA (European Medicines Agency)

univar solutions bv - trientine dihüdrokloriid - hepatolentikulaarne degeneratsioon - muud alimentary seedetrakti ja ainevahetust tooted, - cufence on näidustatud ravi wilsoni tõbi patsientidel talu, d-penitsillamiin ravi, täiskasvanud ja lapsed vanuses 5 aastat ja vanemad.